Posts

The decision, which could be announced as early as Wednesday comes in response to growing pressure from senior Biden officials, who privately urged WHO leaders to change the name.

For years digital health platforms have been integral in helping navigate viral outbreaks such as HIV, COVID-19, and monkeypox. Ramin Bastani, CEO of Healthvana – a platform that delivers test results and records (the company just surpassed 50 million records delivered) to get patients on the right track to receive treatment – talks about how such digital health solutions are improving the response to disease outbreaks.

Dr. Anthony Fauci, the U.S. health official celebrated and vilified as the face of the country’s COVID-19 pandemic response, used his final White House briefing on Tuesday to denounce division and promote vaccines.

RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.

Since the pandemic emerged, more top drugmakers have made progress in improving access to medicines in the developing world, but those gains are largely limited to middle-income countries leaving the poorest behind, an analysis has found.

The European Commission has approved Sanofi and AstraZeneca’s Beyfortus for the prevention of a common and highly contagious type of respiratory infection in infants.

Monkeypox can spread before symptoms appear, British researchers said on Wednesday, providing the first evidence indicating the virus can be transmitted this way.

The potential deal with the U.S. Department of Defense (DoD) would see Moderna’s mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease’s outbreak in Uganda, according to a report.

The company is planning to produce and donate investigational Sudan ebolavirus vaccine to a global non-profit organization’s research program in Uganda, which is facing an outbreak of the disease. The virus circulating in Uganda is the Sudan strain of Ebola, for which there is no proven vaccine.

On a collaboration streak, Merck is pouring a potential $3.5 billion into a partnership with circular RNA company Orna Therapeutics to develop and commercialize multiple oncology and infectious disease programs.